Retroscreen Virology Group PLC Start of hVIVO Challenge Study in Asthma
June 04 2014 - 2:01AM
RNS Non-Regulatory
TIDMRVG
Retroscreen Virology Group PLC
04 June 2014
For immediate release 07.00: 4 June 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
START OF hVIVO CHALLENGE STUDY IN ASTHMA
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce the start
of the Company's first-ever asthma study as it seeks to develop a
safe, reproducible and clinically relevant asthma human challenge
model. The Company is sponsoring the study itself and plans to
launch the model as the first commercially available viral
challenge model for the study of asthma and third party asthma and
antiviral therapies in asthmatic subjects. The model will also
provide Retroscreen with its first samples obtained from subjects
during the course of an asthma exacerbation using its hVIVO
platform.
Retroscreen is developing a range of new human challenge models,
incorporating its viral challenge model concept, to expand its
service offering into new disease areas with high unmet need. These
include respiratory diseases such asthma and Chronic Obstructive
Pulmonary Disease (COPD), where exacerbations are typically caused
by Human Rhinovirus (HRV-16) and other respiratory viruses.
The first subject has now been enrolled in a randomised
double-blind study of the safety and tolerability of asthmatics to
challenge with HRV-16. The aim is to validate the safety and
tolerability of the HRV-16 virus and to assess the impact of
infection with HRV-16 in this asthmatic population. Up to 21
asthmatic subjects, who are currently being treated with
short-acting inhaled <BETA>-agonists alone, will be
inoculated with the challenge virus or placebo. The primary safety
endpoint is the incidence, number and severity of asthma
exacerbations as determined by independent clinical review.
Kym Denny, Chief Executive Officer, commented, "Retroscreen is
expanding the application of its hVIVO platform into new disease
areas with high unmet needs. Asthma represents a major opportunity
for Retroscreen not only to expand its service offering, but also
to gain important insights into a disease that affects millions of
people around the world. We are also preparing to initiate, over
the coming weeks, a viral challenge study in the Over 45's as a
precursor to developing a COPD human challenge model."
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
Retroscreen believes its hVIVO platform has a much wider
application in helping to understand illness better, because the
best way to understand human disease is by studying it in humans,
not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFJMTTMBIMTII
Hvivo (LSE:HVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Sep 2023 to Sep 2024